New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients Notified - ---
M/Y Dagger joins the SEA Index®: HSH Prince Albert II discovers Benetti’s new hybrid yacht Notified -
Flen Health Chooses AGC Biologics to Manufacture Recombinant Enzymes for Next-Generation Wound Treatment Notified -
Univar Solutions Strengthens North American Beauty and Personal Care Portfolio with Exclusive CABB Group Glycolic Acid Distribution Partnership Notified -
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab) Notified -
Hong Kong Tourism Board Makes Monaco Yacht Show Debut to Showcase Ambition as Asia's Leading Yacht Tourism and Marine Business Hub Notified -
Schneider Electric unveils the world’s first fully Software-Defined Medium Voltage switchgear to accelerate the speed and scalability of AI factories Notified -
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition Notified -